ASX:AT1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. More Details


Snowflake Analysis

Exceptional growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has Atomo Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AT1 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.9%

AT1

2.2%

AU Medical Equipment

-0.3%

AU Market


1 Year Return

n/a

AT1

3.3%

AU Medical Equipment

-11.1%

AU Market

Return vs Industry: Insufficient data to determine how AT1 performed against the Australian Medical Equipment industry.

Return vs Market: Insufficient data to determine how AT1 performed against the Australian Market.


Shareholder returns

AT1IndustryMarket
7 Day2.9%2.2%-0.3%
30 Day-10.0%-1.4%-4.2%
90 Day2.9%4.8%1.6%
1 Yearn/a4.6%3.3%-7.8%-11.1%
3 Yearn/a33.6%27.5%17.1%2.1%
5 Yearn/a106.6%92.0%43.1%13.0%

Price Volatility Vs. Market

How volatile is Atomo Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atomo Diagnostics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AT1 (A$0.36) is trading below our estimate of fair value (A$2.27)

Significantly Below Fair Value: AT1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AT1 is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.

PE vs Market: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AT1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AT1 is good value based on its PB Ratio (5.9x) compared to the AU Medical Equipment industry average (6.1x).


Next Steps

Future Growth

How is Atomo Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

85.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AT1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: AT1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AT1's is expected to become profitable in the next 3 years.

Revenue vs Market: AT1's revenue (57.8% per year) is forecast to grow faster than the Australian market (4.4% per year).

High Growth Revenue: AT1's revenue (57.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AT1's Return on Equity is forecast to be high in 3 years time (31.4%)


Next Steps

Past Performance

How has Atomo Diagnostics performed over the past 5 years?

-82.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AT1 is currently unprofitable.

Growing Profit Margin: AT1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AT1's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).


Return on Equity

High ROE: AT1 has a negative Return on Equity (-26.73%), as it is currently unprofitable.


Next Steps

Financial Health

How is Atomo Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: AT1's short term assets (A$33.1M) exceed its short term liabilities (A$1.5M).

Long Term Liabilities: AT1's short term assets (A$33.1M) exceed its long term liabilities (A$112.7K).


Debt to Equity History and Analysis

Debt Level: AT1 is debt free.

Reducing Debt: AT1 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AT1 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AT1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Atomo Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AT1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AT1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AT1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AT1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AT1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average board tenure


CEO

John Kelly

no data

Tenure

Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an ...


Board Members

NamePositionTenureCompensationOwnership
John Kelly
Founderno datano data1.31%
A$ 2.7m
Curt LaBelle
Non-Executive Director3.92yrsno datano data
Constance Carnabuci
Independent Non-Executive Director0.58yrno data0.013%
A$ 27.0k
Paul Kasian
Independent Non-Executive Director0.58yrno data0.018%
A$ 36.0k
John Keith
Independent Non-Executive Chairman6.67yrsno data0.58%
A$ 1.2m
Ian Boulton
Member of Advisory Boardno datano datano data

3.9yrs

Average Tenure

56yo

Average Age

Experienced Board: AT1's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: AT1 only recently listed within the past 12 months.


Top Shareholders

Company Information

Atomo Diagnostics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atomo Diagnostics Limited
  • Ticker: AT1
  • Exchange: ASX
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$202.445m
  • Shares outstanding: 562.35m
  • Website: https://atomodiagnostics.com

Location

  • Atomo Diagnostics Limited
  • Level 2
  • 701-703 Parramatta Road
  • Leichhardt
  • New South Wales
  • 2040
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AT1ASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2020
AT1CHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 2020

Biography

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platf ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 19:09
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.